The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study

By sjmartinez • November 29, 2023

Johnson LF, Myer L, Jamieson L, Meyer-Rath G, Delany-Moretlwe S, Davey DJ. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants: a modelling study. AIDS. 2023 Nov 28. doi: 10.1097/QAD.0000000000003803. Epub ahead of print. PMID: 38016171.

Tags: Infectious Diseases, Publications

Related Posts

Barriers to viral suppression in children aged 9 years or younger on dolutegravir-based antiretroviral therapy in Malawi, a mixed-methods study

Phiri K, Hagstrom C, Lungu E, Balakasi K, Songo J, Makwaya A, Smith D, Worku A, Hoffman R, Phiri S, Dovel K, van Oosterhout JJ.[...]

Single-cell analyses identify monocyte gene expression profiles that influence HIV-1 reservoir size in acutely treated cohorts

Ehrenberg PK, Geretz A, Volcic M, Izumi T, Yum LK, Waickman A, Shangguan S, Paquin-Proulx D, Creegan M, Bose M, Machmach K, McGraw A, Narahari[...]

HIV-Superinfection in Kidney Transplant Recipients with HIV who Received Organs from Donors with HIV

Rozek GM, Yang P, Eby Y, Benner SE, Martens C, Habtehyimer F, Chahoud M, Brown D, Desai NM, Florman S, Rana MM, Pereira MR, Hand[...]